Milestone Pharmaceuticals (MIST) vs Tonix Pharmaceuticals (TNXP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Milestone Pharmaceuticals (MIST) has outperformed Tonix Pharmaceuticals (TNXP) over the past year, losing 84.5% versus a loss of 85.2%. Over five years, MIST leads with a -93.8% price change compared with -100.0% for TNXP. Tonix Pharmaceuticals is the larger company by market cap ($46.2 million vs $46.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MIST | TNXP |
|---|---|---|
| Share price | $0.3711 | $2.38 |
| Market cap | $46.20M | $46.25M |
| 1-day change | -7.06% | -6.67% |
| YTD return | -81.63% | -84.76% |
| 1-year return | -84.54% | -85.22% |
| 5-year return | -93.85% | -100.00% |
| EPS (TTM) | $-0.74 | $-12.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $13.11M |
| Revenue growth (YoY) | — | +29.85% |
| Net income (latest FY) | $-63.06M | $-124.02M |
| Gross margin | — | 49.34% |
| Operating margin | — | -959.05% |
| Net margin | — | -946.22% |
| 52-week high | $3.06 | $20.56 |
| 52-week low | $0.362 | $2.30 |
| Distance from 52-week high | -87.87% | -88.42% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +1479.09% | +1769.75% |
| Average volume | 1.53M | 838.83K |
| Shares outstanding | 124.50M | 19.43M |
| Employees | 38 | 142 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Milestone Pharmaceuticals
MIST stock →Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees
About Tonix Pharmaceuticals
TNXP stock →Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia.
Health Care · Biotechnology: Pharmaceutical Preparations · 142 employees
MIST vs TNXP FAQ
Which is bigger, Milestone Pharmaceuticals or Tonix Pharmaceuticals?
Tonix Pharmaceuticals (TNXP) is larger, with a market capitalization of $46.25M compared with $46.20M for Milestone Pharmaceuticals (MIST).
Which stock has performed better over the past year, MIST or TNXP?
MIST returned -84.54% over the past 12 months, compared with -85.22% for TNXP (price return, excluding dividends). Past performance does not predict future results.
Are Milestone Pharmaceuticals and Tonix Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.